ESLA

Conviction 4HealthcareScan · Thu, Jun 25, 2026

ESLA$0.9550-2.55%

ResistanceSupportVol 14Insider buy

Vol MA14 35.41K

Mar 26Apr 14May 1May 19Jun 8Jun 25

Estrella Immunopharma, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.estrellabio.com ↗

Price0.9550

Change-2.55%

Gap-1.02%

Rel volume0.82×

Avg volume42.4K

Avg $ vol45.37K

SMA 201.06

SMA 501.28

SMA 2001.44

Price vs 50-25.12%

Price vs 200-33.50%

MA stackbearish

50/200 cross—

Supertrenddown · 1.24

RSI (14)36

MACD hist0.00

MACD crossbull · 0d

Stoch %K / %D18 / 24

ADX (14)28

+DI / −DI11 / 20

RSI divergence—

MACD divergence—

ATR %+10.49%

ADR %9.21%

52w high3.05

52w low0.8201

From 52w high-68.69%

Above 52w low+16.45%

New 52w highNo

SqueezeOn · 16d

Bollinger width26.14%

%B0.14

Donchian pos16.18%

Donchian high1.24

Donchian low0.9000

AVWAP (52w high)1.62

vs AVWAP high-41.05%

AVWAP (52w low)1.70

vs AVWAP low-43.85%

OBV trendFlat

Chaikin MF (20)-0.15

Today vs 20d0.82×

Avg vol (14d)35.41K

Avg vol (20d)42.4K

Avg $ vol (20d)45.37K

Market cap41.1M

RS 3m (vs SPY)-11.73%

RS 6m (vs SPY)-49.75%

RS line new highNo

Trend template1/8

Technical rank13.1

1 week-5.45%

1 month-16.96%

3 months-2.57%

6 months-37.58%

1 year-0.52%

YTD-31.29%

P/E-3.15

P/B-7.80

P/S—

P/FCF—

EPS-0.3500

Div yield—

ROE247.87%

ROA-357.20%

Debt/Eq—

Current0.24

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-78.67%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value39.71M

Revenue—

Net income-2.29M

Gross profit—

Free cash flow—

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out43.03M

Employees—

ListedMon, Oct 2, 2023

Free float10.25M

Float %27.1%

Short interest82.6K

Days to cover3.1d

Short volume33.5%

Squeeze score17 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction4 / 100

Pattern quality—

Tech rank13.1 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance1.54

Support0.9600

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ESLA

All disclosures →

No recent disclosed trades by Congress in ESLA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ESLA · 3 buys

Insider	Side	Shares	Value	Traded	Filed
Xu Jiandong Chief Financial Officer · Common Stock, par value $0.0001 per share · 2025-10-07	Buy	1K	$1K	2025-10-07	2026-04-29
Xu Jiandong Chief Financial Officer · Common Stock, par value $0.0001 per share · 2025-09-22	Buy	1K	$1K	2025-09-22	2026-04-29
Xu Jiandong Chief Financial Officer · Common Stock, par value $0.0001 per share · 2025-09-11	Buy	100	$104	2025-09-11	2026-04-29

SEC filings

EDGAR filings in ESLA

EDGAR →

No recent SEC filings on file for ESLA.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.